The pharmaco‐economics of peri‐operative statin therapy
Authors:
- 17 October 2005
- journal article
- Published by Wiley in Anaesthesia
- Vol. 60 (11) , 1059-1063
Abstract
Summary: We analysed the pharmaco‐economics of the prospective peri‐operative studies of statin administration for major elective vascular surgery, using the NHS reference costs for 2004. This analysis suggests that peri‐operative statin therapy for patients undergoing vascular surgery may present the most cost‐effective use of statin therapy yet described, with a number‐needed‐to‐treat of 15 and almost 60% of the total cost of atorvastatin therapy recovered through a reduction in peri‐operative adverse events.Keywords
This publication has 40 references indexed in Scilit:
- Safety of perioperative statin use in high-risk patients undergoing major vascular surgeryThe American Journal of Cardiology, 2005
- Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later timesThe American Journal of Cardiology, 2004
- Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trialJournal of Vascular Surgery, 2004
- Preoperative Thallium Scanning, Selective Coronary Revascularization, and Long-Term Survival After Major Vascular SurgeryCirculation, 2003
- How cost-effective are new preventive strategies for cardiovascular disease?The American Journal of Cardiology, 2003
- Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular SurgeryCirculation, 2003
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease PreventionCurrent Medical Research and Opinion, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998